Trials / Conditions / Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis

13 registered clinical trials studyying Indolent Systemic Mastocytosis — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) NCT07264959	Blueprint Medicines Corporation	—
Recruiting	A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany NCT07255638	Blueprint Medicines Corporation	—
Unknown	Angioedema Biomarker Research Study NCT06210698	Foundation For Rare Disease Research	—
Recruiting	(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Ma NCT04910685	Blueprint Medicines Corporation	Phase 2 / Phase 3
Recruiting	Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis NCT04655118	Telios Pharma, Inc.	Phase 2
Unknown	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment NCT04333108	AB Science	Phase 3
Completed	Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemi NCT03770273	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Active Not Recruiting	(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Ty NCT03731260	Blueprint Medicines Corporation	Phase 2
Completed	Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language NCT03632811	University Hospital, Toulouse	—
Completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 NCT02808793	Allakos Inc.	Phase 1
Completed	Treatment of Indolent Systemic Mastocytosis With PA101 NCT02478957	Patara Pharma	Phase 2
Unknown	Midostaurin in Indolent Systemic Mastocytosis NCT01920204	University Medical Center Groningen	Phase 2
Completed	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis NCT00814073	AB Science	Phase 3